Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

fering the possibility of maintaining remission without the serious complications associated with the current standard of care.  Additionally, these data provide a powerful validation of targeting the chemokine system to treat major inflammatory and autoimmune diseases."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

This randomized, placebo-controlled, double-blind clinical trial of 436 patients was comprised of three discrete periods which allowed for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The 12-week Induction period of the study was followed by a 4-week, open-label period, during which all subjects received Traficet-EN. Patients who achieved a pre-specified 70-point or greater reduction in CDAI were re-randomized to active drug or placebo for an additional 36-week Maintenance period, thereby permitting an evaluation of the drug's ability to maintain a treatment response. CDAI is a research tool used for determining a patient's level of disease activity and is the key measure regarded by regulatory agencies as an appropriate endpoint to assess the efficacy of a drug for the treatment of Crohn's disease.

About Traficet-EN™ (CCX282-B)


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
(Date:10/22/2014)... 2014 Influenza will affect as many as 200,000 ... the United States as high as 49,000 people.  ... is from person to person in respiratory droplets of coughs ... of death, but kills much fewer people each year than ... human fluids including sweat, saliva, blood and other bodily fluids. ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter TUESDAY, ... diagnosed with Ebola while working for NBC News in ... the special isolation unit at Nebraska Medical Center in Omaha, where ... said Tuesday. A blood test confirmed by the U.S. Centers ... head home to Providence, R.I., NBC News reported Tuesday ...
(Date:10/20/2014)... With a mere 19 days to November 4, ... fundraising stop at the  Law Offices of Dan ... debate last night with his opponent Gov. Rick Scott, ... seven minutes because Crist had an electric fan underneath ... one word: "weird." , Before touching on his well-known ...
(Date:10/20/2014)... 20, 2014 The Advocator Group, ... at the American Foundation for Suicide Prevention’s (AFSP) Out ... is a not-for-profit organization that hosts hundreds of community ... these events are used to help understand and prevent ... personal relationships as well. , The Advocator Group ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, ... Columbus, Inc., A Division of MaternOhio Clinical Associates, Inc., ... 100,000 patients annually. Dr. Murphy will provide a full ... a women’s life. She is accepting new patients at ... Dublin. , Dr. Murphy offers a wide variety of ...
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
Breaking Medicine News(10 mins):Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... and into woman,s body cavity , , FRIDAY, Aug. 8 ... the first operation of its kind in the United ... removed a woman,s gallbladder without making any external incisions. ... ongoing clinical research trial, involved insertion of an endoscope ...
... Men Living in Senior Housing Growing; Adoption of Healthy Lifestyle ... ... -. In the face of conventional,wisdom, which has long proven true, women ... more men than ever are moving,into senior living residences nationwide. Historically female-dominated,senior ...
... and,Palliative Care Organization and National Hospice Foundation honor ... This prestigious award,celebrates innovation in end-of-life care and ... Award recipients were announced July 25 at ... This year,s Award winners are:, -- Pain ...
... HIV transmission and the degree to which people are able ... words, hope, have been overlooked in policies to tackle HIV/AIDS. ... Council (ESRC) argues that hope is a powerful tool in ... 30 years into the AIDS epidemic a medical vaccine for ...
... Summer ... Internship, ... across southwestern Pennsylvania,and the Pittsburgh region, have taken part in the ... goal of the program is to expose greatly increased numbers of ...
... of victims get to hospital quickly enough to limit damage, ... people who have strokes don,t act quickly enough to get ... study finds. , "One of the problems is that a ... stroke," said Kathryn M. Rose, a research associate professor of ...
Cached Medicine News:Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:More Men Moving Into Senior Residences 2Health News:More Men Moving Into Senior Residences 3Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 2Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 3Health News:Hope: An overlooked tool in the battle against HIV/AIDS 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Many Miss Out on Stroke Treatment 2Health News:Many Miss Out on Stroke Treatment 3
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
With a large white surface and a black X in the center, knockout really makes you look the heavyweight....
Icefire has ice crystals on the top of a cool blue iris....
This design features a solid red iris....
Medicine Products: